13F Pro13F Pro

Blue Owl Capital Holdings LP

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1858703
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare44.1%$290.2M
  • Technology38.5%$253.5M
  • Other7.5%$49.2M
  • Financials4.1%$26.7M
  • Industrials2.8%$18.5M
  • Utilities2.2%$14.7M
  • Real Estate0.5%$3.2M
  • Consumer Discretionary0.2%$1.3M
  • Materials0.1%$401,958
  • Energy0.0%$101,833

AUM History

13fpro.ai/research/fund/blue-owl-capital-holdings-lp-1858703

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/blue-owl-capital-holdings-lp-1858703

Blue Owl Capital Holdings LP 13F holdings — Q2 2026

$664.5M portfolio (+78.5% QoQ) · 76 holdings · Q2 2026 13F · top 10 are 79% of the stock portfolio

Includes $6.5M of put/call options ($0 puts, $6.5M calls), which 13F rules report at the value of the underlying shares, not the premium at risk. Stocks alone: $658.0M. Weights use the stock portfolio.

All holdings — Blue Owl Capital Holdings LP (Q2 2026)

76 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
HLLY$HLLYHolley Inc.$11.2M+3%
EYPT$EYPTEyePoint, Inc.$10.9M-16%
SGMT$SGMTSagimet Biosciences Inc.$9.7M+278%
CRVS$CRVSCorvus Pharmaceuticals, Inc.$9.1M+12%
ARTV$ARTVArtiva Biotherapeutics, Inc.$8.5MNew
CMPX$CMPXCompass Therapeutics, Inc.$7.9M+23%
CNDT$CNDTCONDUENT Inc$7.4M—
RYTM$RYTMRHYTHM PHARMACEUTICALS, INC.$6.8M—
CMPS$CMPSCOMPASS Pathways plcadr$6.4M-75%
RARE$RAREUltragenyx Pharmaceutical Inc.$6.1M-40%
PVLA$PVLAPALVELLA THERAPEUTICS, INC.$5.5M+16%
IMA$IMAImageneBio, Inc.$5.4M-4%
CMPS$CMPSCALLCOMPASS Pathways plc$5.2MNew
VRDN$VRDNViridian Therapeutics, Inc.\DE$4.8MNew
IMMX$IMMXImmix Biopharma, Inc.$4.5M-20%

What changed in Q2 2026

Against the previous quarter's 13F: 20 new, 11 added to, 16 trimmed, 14 sold out. Share-count changes; largest moves by dollar size first.

New positions (20)

  • SPCX$SPCXSPACE EXPLORATION TECHNOLOGIES CORP$239.0M

    first bought this quarter

  • COF$COFCAPITAL ONE FINANCIAL CORP$24.0M

    first bought this quarter

  • FISN$FISNDEEP FISSION, INC.$14.7M

    first bought this quarter

  • ARTV$ARTVArtiva Biotherapeutics, Inc.$8.5M

    first bought this quarter

  • CMPS$CMPSCALLCOMPASS Pathways plc$5.2M

    first bought this quarter

  • VRDN$VRDNViridian Therapeutics, Inc.\DE$4.8M

    first bought this quarter

+14 more in the Excel export

Added to (11)

  • DELL$DELLDell Technologies Inc.+137%

    now $14.2M · held 2+ qtrs

  • SGMT$SGMTSagimet Biosciences Inc.+278%

    now $9.7M · held 2+ qtrs

  • LRMR$LRMRLarimar Therapeutics, Inc.+29%

    now $27.9M · held 2+ qtrs

  • ORIC$ORICOric Pharmaceuticals, Inc.+167%

    now $4.3M · held 2+ qtrs

  • CMPX$CMPXCompass Therapeutics, Inc.+23%

    now $7.9M · held 2+ qtrs

  • LENZ$LENZLENZ Therapeutics, Inc.+49%

    now $4.3M · held 2+ qtrs

+5 more in the Excel export

Trimmed (16)

  • CMPS$CMPSCOMPASS Pathways plc-75%

    now $6.4M · held 2+ qtrs

  • MPLT$MPLTMapLight Therapeutics, Inc.-27%

    now $26.2M · held 2+ qtrs

  • CGEM$CGEMCullinan Therapeutics, Inc.-19%

    now $28.0M · held 2+ qtrs

  • RARE$RAREUltragenyx Pharmaceutical Inc.-40%

    now $6.1M · held 2+ qtrs

  • ELDN$ELDNEledon Pharmaceuticals, Inc.-60%

    now $2.2M · held 2+ qtrs

  • AKTS$AKTSAktis Oncology, Inc.-3%

    now $99.0M · held 2+ qtrs

+10 more in the Excel export

Sold out (14)

  • CVEO$CVEOCiveo Corpwas $4.8M

    held 5+ qtrs

  • KALV$KALVKalVista Pharmaceuticals, Inc.was $4.3M

    held 3+ qtrs

  • OVID$OVIDOvid Therapeutics Inc.was $4.2M

    held 1+ qtrs

  • PLRX$PLRXPLIANT THERAPEUTICS, INC.was $3.7M
  • EPD$EPDENTERPRISE PRODUCTS PARTNERS L.P.was $1.2M
  • SYNTEC OPTICS HLDGS INCwas $867K

+8 more in the Excel export

Share

Holdings by quarter

Every 13F Blue Owl Capital Holdings LP has filed, 18 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow Blue Owl Capital?

Q2 2026 13F filed with the SEC on Aug 11, 2026. Prices are closing prices as of Oct 26, 2026.

Average quality of Blue Owl Capital's top 20 holdings: 49/100 (our AI quality score, weighted by position size; 10 of the 20 are scored)

Top 10 since filing

-11.7%

Value-weighted move of the 10 largest stock positions

Turnover

15%

Last quarter

Top 10 weight

79%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

0%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q1 2026 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

Blue Owl Capital Holdings LP disclosed 76 positions worth $664.5M in its Form 13F-HR for Q2 2026 — $658.0M in common stock plus $6.5M of put/call option positions (reported at underlying notional value, not premium at risk), led by $SPCX (SPACE EXPLORATION TECHNOLOGIES CORP) at 36.3% of the equity portfolio, followed by $AKTS and $CGEM. During the quarter the fund opened 20 new positions and exited 14 — including a new stake in $SPCX and a full exit from $CVEO. The portfolio is most concentrated in Healthcare (44.1% of disclosed assets). All figures are sourced directly from Blue Owl Capital Holdings LP’s Form 13F-HR filing with the SEC under CIK 1858703.

Funds like this

managers whose biggest positions overlap Blue Owl Capital's
a16z Capital Management, L.L.C.$14.21B 13F book · 3 shared top holdingsSPCXERASAKTSMPM BioImpact LLC$1.64B 13F book · 6 shared top holdingsAKTSCGEMRAREPVLAContrarius Group Holdings Ltd$2.17B 13F book · 3 shared top holdingsSPCXDELLWWEcoR1 Capital, LLC$2.06B 13F book · 3 shared top holdingsAKTSORICERASBVF INC/IL$3.91B 13F book · 5 shared top holdingsCGEMPVLASGMTELDNSUVRETTA CAPITAL MANAGEMENT, LLC$5.47B 13F book · 3 shared top holdingsEYPTCOFPVLA

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: Blue Owl Capital Holdings LP

13F Pro is an AI hedge fund tracker and stock research platform. For Blue Owl Capital Holdings LP (SEC CIK: 1858703), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in Blue Owl Capital Holdings LP's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.